IL6 and head and neck squamous cell carcinoma: Based on evidence in preclinical models and the finding that serum IL-6 was a biomarker of resistance to cetuximab-containing therapy in a Phase II trial [17], we initially hypothesized that IL-6 mediated cetuximab resistance in HNSCC cells and that targeting the IL-6 pathway could overcome cetuximab resistance.